Investment Summary |
|
|---|---|
| Date | 2021-07-29 |
| Target | Immuneering |
| Sector | Life Science |
| Sellers(s) | Teva Pharmaceutical Industries |
| Deal Type | IPO |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1901 |
| Sector | Life Science |
| Employees | 37,000 |
| Revenue | 16.5B USD (2024) |
Teva Pharmaceutical Industries is a provider of pharmaceutical products, committed to increasing access to high-quality healthcare by developing, producing, and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva Pharmaceutical Industries was founded in 1901 and is based in Tel Aviv, Israel.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 9 |
| Sector: Life Science M&A | 8 of 8 |
| Type: IPO M&A Deals | 1 of 1 |
| State: Massachusetts M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2021 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-04-01 |
Zdravlje
Leskovac, Serbia Zdravlje is a manufacturer and supplier of high-quality pharmaceutical products. The Company currently manufactures a large portfolio of oral solid and liquid products to treat a range of serious and chronic diseases including cardiovascular, central nervous system, and respiratory disorders, amongst others. It supplies high-quality pharmaceuticals to more than 35 international markets including those in Western & Eastern Europe, U.K., Asia-Pacific, Sub-Saharan Africa, and Latin America. Zdravlje was formed in 1953 and is based in Leskovac, Serbia. |
Sell | - |